Anika Therapeutics, Inc.ANIKNASDAQ
Loading
Year-over-year operating cash flow growth rate
Latest
-32.50%
↓ 132% vs avg
Percentile
P54
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
100.04%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -32.50% |
| Q3 2025 | 3734.92% |
| Q2 2025 | -45.38% |
| Q1 2025 | -108.22% |
| Q4 2024 | -68.46% |
| Q3 2024 | 569.22% |
| Q2 2024 | -748.41% |
| Q1 2024 | -103.46% |
| Q4 2023 | -43.90% |
| Q3 2023 | 178.20% |
| Q2 2023 | -129.22% |
| Q1 2023 | -852.18% |
| Q4 2022 | -82.24% |
| Q3 2022 | -12.27% |
| Q2 2022 | 265.22% |
| Q1 2022 | -141.79% |
| Q4 2021 | 116.88% |
| Q3 2021 | -51.98% |
| Q2 2021 | 276.64% |
| Q1 2021 | -193.97% |
| Q4 2020 | -55.89% |
| Q3 2020 | 64.38% |
| Q2 2020 | 241.44% |
| Q1 2020 | -91.98% |
| Q4 2019 | 29.56% |
| Q3 2019 | 83.75% |
| Q2 2019 | -35.36% |
| Q1 2019 | -15.49% |
| Q4 2018 | -7.65% |
| Q3 2018 | 142.50% |
| Q2 2018 | -53.39% |
| Q1 2018 | 37.40% |
| Q4 2017 | -42.31% |
| Q3 2017 | 92.95% |
| Q2 2017 | -59.44% |
| Q1 2017 | 164.54% |
| Q4 2016 | -48.35% |
| Q3 2016 | 1191.03% |
| Q2 2016 | -113.50% |
| Q1 2016 | -49.72% |